Sol Gel Technologies Ltd. (SLGL) PT Lowered to $14 at Jefferies

Jefferies analyst David Steinberg lowered the price target on Sol Gel Technologies Ltd. (NASDAQ: SLGL) to $14.00 (from $16.00) while maintaining a Buy rating.

The analyst commented, "Q3 revenue of ~$9M missed our estimate on timing of licensing payments, with partial
offsets from lower OpEx. We update our model to reflect the Nov 4th sale of the generic dermatology business to Padagis. Key NT drivers for SLGL will be the launches early next year of novel acne and rosacea products Twyneo & Epsolay by global dermatology leader Galderma. Post the Padagis divestiture, our updated PT is $14, based on 23x FY26E EPS of $0.88, discounted back 12%."

You May Also Be Interested In

• Monopar Therapeutics (MNPR) PT Raised to $133 at BTIG
• Toei co Ltd (9605:JP) PT Raised to JPY6,100 at Nomura/Instinet
• Nomura/Instinet Downgrades Pearl Abyss Corp. (263750:KS) (BRFS) to Neutral